INCB7839
- Generic Name
- INCB7839
- Drug Type
- Small Molecule
- Background
INCB7839 is a novel, orally available ADAM metalloprotease inhibitor that is designed to block activation of the epidermal growth factor (EGFR) pathways. It represents a potentially important new class of targeted breast cancer therapy. It has shown promising clinical activity in heavily pretreated, refractory breast cancer patients.
- Indication
Investigated for use/treatment in breast cancer.
INCB7839 in Treating Children With Recurrent/Progressive High-Grade Gliomas
- Conditions
- Glioblastoma MultiformeAnaplastic OligodendrogliomaHigh-grade Astrocytoma NOSAnaplastic AstrocytomaDIPGCNS Primary Tumor, NOS (Malignant Glioma)
- Interventions
- First Posted Date
- 2020-03-04
- Last Posted Date
- 2025-02-19
- Lead Sponsor
- Pediatric Brain Tumor Consortium
- Target Recruit Count
- 13
- Registration Number
- NCT04295759
- Locations
- 🇺🇸
Stanford University and Lucile Packard Children's Hospital, Palo Alto, California, United States
🇺🇸Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸Cincinnati Children Hospital Medical Center, Cincinnati, Ohio, United States
ADAM17 Inhibitor/ Rituximab After Auto HCT for DLBCL
- Conditions
- Diffuse Large B Cell Non-Hodgkin Lymphoma
- Interventions
- First Posted Date
- 2014-05-19
- Last Posted Date
- 2020-02-19
- Lead Sponsor
- Masonic Cancer Center, University of Minnesota
- Target Recruit Count
- 30
- Registration Number
- NCT02141451
- Locations
- 🇺🇸
University of Minnesota Medical Center, Fairview, Minneapolis, Minnesota, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.